Insider Transactions in Q2 2024 at Bei Gene, Ltd. (BGNE)
Insider Transaction List (Q2 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 24
2024
|
Xiaobin Wu President, COO & GM China |
SELL
Open market or private sale
|
Direct |
1,459
-88.52%
|
$233,440
$160.39 P/Share
|
|
Jun 24
2024
|
Lai Wang Global Head of R&D |
SELL
Open market or private sale
|
Direct |
1,064
-99.91%
|
$170,240
$160.45 P/Share
|
|
Jun 24
2024
|
Julia Aijun Wang Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
899
-100.0%
|
$139,345
$155.66 P/Share
|
|
Jun 24
2024
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,789
-92.83%
|
$443,451
$159.81 P/Share
|
|
Jun 18
2024
|
Xiaobin Wu President, COO & GM China |
SELL
Open market or private sale
|
Direct |
2,627
-63.21%
|
$404,558
$154.95 P/Share
|
|
Jun 18
2024
|
Lai Wang Global Head of R&D |
SELL
Open market or private sale
|
Direct |
841
-100.0%
|
$128,673
$153.75 P/Share
|
|
Jun 17
2024
|
Xiaobin Wu President, COO & GM China |
SELL
Open market or private sale
|
Direct |
627
-19.27%
|
$99,693
$159.0 P/Share
|
|
Jun 17
2024
|
Lai Wang Global Head of R&D |
SELL
Open market or private sale
|
Direct |
1,500
-22.24%
|
$238,500
$159.2 P/Share
|
|
Jun 17
2024
|
Julia Aijun Wang Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
916
-46.76%
|
$144,728
$158.89 P/Share
|
|
Jun 17
2024
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,281
-61.66%
|
$203,679
$159.28 P/Share
|
|
Jun 17
2024
|
Chan Henry Lee SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
439
-61.65%
|
$69,801
$159.21 P/Share
|
|
Jun 05
2024
|
Xiaobin Wu President, COO & GM China |
BUY
Grant, award, or other acquisition
|
Direct |
253,409
+16.65%
|
-
|
|
Jun 05
2024
|
Titus B. Ball Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,427
+33.77%
|
-
|
|
Jun 05
2024
|
Anthony C Hooper Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,341
+23.31%
|
-
|
|
Jun 05
2024
|
Olivier Brandicourt Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,341
+50.0%
|
-
|
|
Jun 05
2024
|
Margaret Dugan Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,341
+26.23%
|
-
|
|
Jun 05
2024
|
Chan Henry Lee SVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
98,085
+26.69%
|
-
|
|
Jun 05
2024
|
Lai Wang Global Head of R&D |
BUY
Grant, award, or other acquisition
|
Direct |
168,935
+8.72%
|
-
|
|
Jun 05
2024
|
Corazon (Corsee) D. Sanders Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,341
+26.11%
|
-
|
|
Jun 05
2024
|
Xiaodong Wang Director |
BUY
Grant, award, or other acquisition
|
Direct |
108,992
+1.92%
|
-
|
|
Jun 05
2024
|
Alessandro Riva Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,341
+26.23%
|
-
|
|
Jun 05
2024
|
Donald W. Glazer Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,341
+0.6%
|
-
|
|
Jun 05
2024
|
John Oyler Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
490,464
+21.3%
|
-
|
|
Jun 05
2024
|
Julia Aijun Wang Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
136,240
+22.99%
|
-
|
|
Jun 05
2024
|
Qingqing Yi Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,341
+26.23%
|
-
|
|
Jun 05
2024
|
Baker Bros. Advisors LP |
BUY
Grant, award, or other acquisition
|
Indirect |
65,364
+20.58%
|
-
|
|
Apr 11
2024
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
12,084
-67.24%
|
$1,764,264
$146.88 P/Share
|
|
Apr 10
2024
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
26,716
-23.46%
|
$3,980,684
$149.55 P/Share
|
|
Apr 09
2024
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
11,200
-7.86%
|
$1,713,600
$153.32 P/Share
|